KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Operating Expenses (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Other Operating Expenses for 15 consecutive years, with $65.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 46.07% to $65.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $189.4 million, a 26.48% increase, with the full-year FY2025 number at $189.4 million, up 26.48% from a year prior.
  • Other Operating Expenses was $65.3 million for Q4 2025 at Supernus Pharmaceuticals, up from $43.3 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $65.3 million in Q4 2025 to a low of $22.2 million in Q2 2021.
  • A 5-year average of $40.6 million and a median of $41.3 million in 2021 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: surged 662.26% in 2021, then decreased 26.34% in 2024.
  • Supernus Pharmaceuticals' Other Operating Expenses stood at $30.1 million in 2021, then skyrocketed by 36.86% to $41.2 million in 2022, then soared by 47.11% to $60.7 million in 2023, then fell by 26.34% to $44.7 million in 2024, then surged by 46.07% to $65.3 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Other Operating Expenses are $65.3 million (Q4 2025), $43.3 million (Q3 2025), and $37.6 million (Q2 2025).